>>> US Research Calls I

Research Calls I
  • Upgrades:
    • Autolus Therapeutics (AUTL) upgraded to Buy from Neutral at Redburn Atlantic; tgt $13
    • Bloom Energy (BE) upgraded to Overweight from Neutral at Piper Sandler; tgt raised to $20
    • BrightView (BV) upgraded to Outperform from Mkt Perform at William Blair
    • Descartes (DSGX) upgraded to Equal Weight from Underweight at Barclays; tgt raised to $125
    • Independence Realty Trust (IRT) upgraded to Market Perform from Underperform at BMO Capital Markets; tgt raised to $21
  • Downgrades:
    • Alexandria RE (ARE) downgraded to Hold from Buy at Deutsche Bank; tgt lowered to $112
    • Bionano Genomics (BNGO) downgraded to Neutral from Buy at Ladenburg Thalmann
    • Bluebirdbio (BLUE) downgraded to Neutral from Buy at BofA Securities; tgt lowered to $0.50
    • Bluebirdbio (BLUE) downgraded to Underweight from Neutral at JP Morgan
    • Diamondrock Hospitality (DRH) downgraded to In-line from Outperform at Evercore ISI; tgt $10.50
    • Digital Turbine (APPS) downgraded to Underperform from Neutral at BofA Securities; tgt $1
    • European Wax Center (EWCZ) downgraded to Underweight from Equal-Weight at Morgan Stanley; tgt $5
    • GlaxoSmithKline (GSK) downgraded to Hold from Buy at Deutsche Bank
    • Gogoro (GGR) downgraded to Neutral from Buy at Citigroup; tgt lowered to $0.50
  • Others:
    • AbbVie (ABBV) initiated with an Outperform at Wolfe Research; tgt $205
    • Alaska Air (ALK) resumed with a Buy at Goldman; tgt $70
    • Allegiant Travel (ALGT) resumed with a Neutral at Goldman; tgt $83
    • American Airlines (AAL) resumed with a Neutral at Goldman; tgt $15
    • Amgen (AMGN) initiated with a Peer Perform at Wolfe Research
    • Biogen (BIIB) initiated with a Peer Perform at Wolfe Research
    • BioMarin Pharmaceutical (BMRN) initiated with an Outperform at Wolfe Research; tgt $95
    • Bristol-Myers (BMY) initiated with a Peer Perform at Wolfe Research
    • CDW (CDW) initiated with a Buy at Redburn Atlantic; tgt $230
    • Chipotle Mexican Grill (CMG) resumed with an Outperform at RBC Capital Mkts; tgt $70
    • Comfort Systems (FIX) initiated with a Buy at Stifel; tgt $524
    • Core Scientific (CORZ) initiated with a Buy at ROTH MKM; tgt $25.50
    • Delta Air Lines (DAL) resumed with a Buy at Goldman; tgt $83
    • Doximity (DOCS) initiated with a Neutral at Goldman; tgt $58
    • EMCOR Group (EME) initiated with a Buy at Stifel; tgt $600
    • Everus (ECG) initiated with a Buy at Stifel; tgt $71
    • First Advantage Corp. (FA) resumed with an Outperform at RBC Capital Mkts; tgt $22
    • Gilead Sciences (GILD) initiated with an Outperform at Wolfe Research; tgt $110
    • GRAIL (GRAL) initiated with a Peer Perform at Wolfe Research
    • HealthEquity (HQY) initiated with a Neutral at Goldman; tgt $108

FT : How London snared France’s Canal+ to revive moribund listing market

How London snared France’s Canal+ to revive moribund listing market
Expected €6bn-€8bn IPO is set to be the largest listing in City since 2022

The irony that a French company is set to become the largest flotation in London for more than two years, a time when homegrown corporate successes have shifted to the US, has not been lost on bankers in the City. 

Canal+ is not just any French company, but one that carries deep “cultural significance” across the channel, according to Maxime Saada, who heads the streaming giant and film producer that is part of Vivendi, the media conglomerate controlled by the billionaire Bolloré family. 

Coming just weeks after Canal+ put on the Paddington in Peru premiere in London, the UK stock exchange has rolled out its own version of a red carpet after ministers overhauled and streamlined listing rules for the first time in 30 years this summer. Saada said that London’s markets revamp “to make it as easy, as smooth as possible” was a major factor in picking the UK capital.

Canal+, which has a book value of close to €7bn, is expected to have a market capitalisation of between €6bn and €8bn, said people close to the listing. This would make it the largest primary listing in London since Haleon was spun out of GSK in 2022 at a market valuation of about £30bn, during a period of remarkable drought for a global stock exchange that led to concerns over its rules and lack of domestic UK investor appetite. 

Canal+, which has produced hits including Versailles, is the largest of three businesses being spun out of Vivendi. If a $2.9bn deal to acquire South Africa’s MultiChoice completes early next year, the combined business could be worth as much as €10bn, according to those close to the deal.

With the Bollorés having long argued that the French market’s valuation of the Vivendi business is less than the sum of its parts, the split will test how much more the company’s divisions will be valued separately.

Saada now needs to convince UK investors that Canal+ — like Paddington — has found its right home in London, with plans to use the country as a launch pad for global expansion that he hopes could double the size of the business.

There have been just over a dozen primary listings in London this year, according to data compiled by MKP Advisors, the biggest of which was Raspberry Pi at about £540mm. Bankers struggle to remember the last time that a major French company has crossed the channel for London.

Speaking in an office in the Parisian suburb of Issy-les-Moulineaux that will continue to be the headquarters for Canal+, Saada admits that the decision to relocate the company’s ownership to the London stock exchange disappointed some in the Elysée.

He has sought to allay concerns in France — where it will also continue paying tax — but has also made it clear that the future of the company lies elsewhere, with London bringing greater visibility as a global company and access to international investors. 

“I believe [the French authorities] are relieved that the company headquarters and tax structure is [in] France. We’re not the first French company [to list elsewhere]. Of course, there are some adverse reactions and some people are disappointed. But when we tell our story . . . they understand.”

Canal+ has close to 27mn subscribers to its streaming and TV platforms across 50 countries, of which about 60 per cent are outside France, alongside a TV and films studio arm. In the first nine months of 2024, the company reported a 3.2 per cent rise in revenues to €4.72bn.

“When we look at the path for the future, the partners, the competitors, the markets, the investors, almost all of them are English speaking,” said Saada.

“We used to be a French company, completely relying on the French market for its revenues, its profits, its rights and most of its stuff. And we have transformed into a company that is now international. I cannot say global yet, but that’s the plan.”

M&A will form part of this plan. Adding MultiChoice’s African business, Canal+ will have more than 40mn subscribers; Saada wants to take this to 100mn.

“We don’t want to overextend ourselves, and we’re very careful on the way we spend money. But we need scale. At 27mn [subscribers], you are already a sizeable player. At 40mn/50mn, you are definitely a contender. Higher than that, it’s interesting. That is the only topic.”

Canal+ is already considering taking a majority stake in Asian streamer Viu, while Saada says that Viaplay, the Scandinavian steaming service, could be another potential target. 

Vivendi became the largest shareholder after an emergency recapitalisation of the Nordic media company this year, although it has signed a standstill agreement with the second-biggest investor, the Czech group PPF.

“It’s a possibility. And there are others. If you look at significant pay TV players in the world, there are others. I want to be in a position where we can be a consolidator,” said Saada.

He says that the company was attracted by the new flexibility in rules for the London stock exchange, with the company in effect set to operate a hybrid of French rules allowed under its incorporation in that country and London’s regime.

“We started speaking [with the LSE] about what it means to be a company headquartered in France and listed in the UK. We are the only of our kind, I believe. So it means that not all rules will apply to us.”

These include London’s rules that board members be subject to re-election annually, he said, with Vivendi instead implementing the French standard of more than three years. The Bolloré family will also retain a stake of about 30 per cent in London-listed Canal+, equivalent to what it owns in Vivendi.

As a result, Canal+ is unlikely to be eligible for inclusion in the FTSE 100 rankings. But Saada said that the company was already attracting interest from investors in the UK, even if the company was still not clearly understood by all in the market. He pointed to the need to show the capabilities of the company’s streaming platform, which bundles together content from most of the large US streamers as well as hundreds of live channels and sports. 

Not all existing investors are happy, however. Paris-based asset manager CIAM has raised concerns that minority shareholders will take a hit and that the plan will not close the conglomerate discount. It also warned that the family could also increase its stake without launching a full takeover.

Vivendi declined at the time to comment but a person with knowledge of the situation said the group’s plan “was built on shareholder democracy”.

Saada added: “My focus is, and I believe that is what the Bollorés have proven in the past, to increase the valuation of the company for all shareholders.” 

The decision to split Vivendi is subject to a shareholder meeting on December 9, which requires two-thirds of votes to pass. Saada is confident that it will.

By mid-December, he hopes to be at the front of London’s stock exchange to celebrate its first day of trading. And, despite requests, he says Paddington and his marmalade sandwiches will not be with him this time.

FT : Valuations at Elon Musk’s SpaceX and xAI set to soar in new deals

Valuations at Elon Musk’s SpaceX and xAI set to soar in new deals
Billionaire’s rocket builder plots huge share sale while AI start-up closes in on $5bn funding round

Two of Elon Musk’s private companies are set to secure multibillion-dollar jumps in valuation through new deals, as investors race to back the sprawling business interests of the world’s richest man.

SpaceX, the largest private company in the US, is preparing to launch a tender offer in December that will sell existing shares in the business at about $135 each, according to people with knowledge of the discussions. That would value the rocket builder at more than $250bn, up from about $210bn during a similar deal earlier this year.

Meanwhile, Musk’s artificial intelligence start-up xAI has raised $5bn at a valuation of $45bn, almost double its valuation a few months ago, according to the people. The fundraising has been carried out at breakneck speed as discussions between Musk and his investors began just last month.

The double fundraising comes as Musk expands his focus beyond Silicon Valley to Washington DC, having helped to deliver the US election to Donald Trump earlier this month and becoming a key confidant to the president-elect.

On Tuesday, Trump appointed Musk and Vivek Ramaswamy, a biotech entrepreneur and former presidential hopeful, to lead a new “department of government efficiency”. It will “provide advice and guidance from outside of government” and look for ways to “dismantle” bureaucracy, Trump said in a statement.

Musk’s proximity to Trump has also helped to boost the share price of Tesla, the electric vehicle-maker he runs as chief executive, by almost 30 per cent since the November 5 election.

The people close to the xAI fundraising said the deal had been “fully allocated”, meaning all of the new shares had been assigned to investors, although it will not formally close until the end of the month. They added that the deal was oversubscribed and featured only investors who had backed the start-up in its previous fundraising round.

The significant interest in xAI, which operates a ChatGPT rival called Grok, has fuelled Musk’s efforts to compete with rivals such as OpenAI and Anthropic.

It has also already prompted speculation about a subsequent fundraising in the first quarter of next year that could value the company as high as $75bn, according to two of the people. However, it was not yet clear if this had been communicated directly to investors by xAI.

xAI has been developing an enormous cluster of 100,000 graphics processing units, the chips used to train and run AI tools, in Memphis. The project, nicknamed Colossus, would be one of the biggest supercomputers in the world. Musk’s AI systems are likely to play a critical role across his many enterprises, which include X, Tesla, SpaceX and Neuralink.

SpaceX is also likely to benefit from closeness to Trump. As well as a long-stated ambition to launch a mission to Mars, Musk wants to add to the company’s network of 6,000 low Earth orbit satellites that constitute its Starlink broadband network. The billionaire has also regularly fought battles with an array of US regulators that he believes have stymied Tesla and SpaceX.

Musk and SpaceX did not immediately respond to requests for comment.

NYT : Elon Musk Met With Iran’s U.N. Ambassador, Iranian Officials Say

Elon Musk Met With Iran’s U.N. Ambassador, Iranian Officials Say
The tech billionaire, a top adviser to President-elect Donald J. Trump, was reported to have discussed ways to defuse tensions between Iran and the United States.

Elon Musk, a close adviser to President-elect Donald J. Trump, met with Iran’s ambassador to the United Nations on Monday in New York in a session that two Iranian officials described as a discussion of how to defuse tensions between Iran and the United States.

The Iranians said the meeting between Mr. Musk and Ambassador Amir Saeid Iravani lasted more than an hour and was held at a secret location. The Iranians, who spoke on the condition of anonymity because they were not authorized to discuss policy publicly, described the meeting as “positive” and “good news.”

Asked about whether there was such a session, Steven Cheung, Mr. Trump’s communications director, said, “We do not comment on reports of private meetings that did or did not occur.” Mr. Musk did not respond to a request for comment.

Karoline Leavitt, the transition spokeswoman for the incoming Trump-Vance administration, said in a statement: “The American people re-elected President Trump because they trust him to lead our country and restore peace through strength around the world. When he returns to the White House, he will take the necessary action to do just that.”

An early direct meeting between a senior Iranian official and Mr. Musk raises the possibility of a change in tone between Tehran and Washington under the Trump administration, despite a charged history between the president-elect and Iran. One of the Iranian officials said that it was Mr. Musk who had requested the meeting and that the ambassador picked the site.

During his first term Mr. Trump pulled the United States out of the 2015 nuclear accord between Iran and world powers, calling it “a horrible one-sided deal that should have never, ever been made,” and imposed tough economic sanctions on Iranian oil revenues and international banking transactions. He also ordered the assassination of a top Iranian general, Qassim Suleimani, in Iraq in 2020.

In response, Iran’s supreme leader banned any negotiations with the Trump administration and Iranian officials vowed to avenge Mr. Suleimani’s killing. Federal prosecutors said in a court filing last week that Iran had plotted to assassinate Mr. Trump before the election.

But in the wake of Mr. Trump’s election last week, Iran has been openly debating whether it can now reach a new and more lasting deal with the United States. Many members of President Masoud Pezeshkian’s new government favor negotiating, arguing that Mr. Trump likes to make deals and that there may be an opportunity to get the sanctions lifted.

Many in the conservative faction in Iran oppose engagement with Mr. Trump, and any negotiations — or deal — must be approved by the supreme leader, Ayatollah Ali Khamenei. Mr. Trump has been an avid supporter of Israel, which has been waging war on the Iranian-backed militias Hamas and Hezbollah since the Oct. 7 attack last year.

On Thursday, in a post on X, Iran’s foreign minister, Abbas Araghchi, said: “Differences can be resolved through cooperation and dialogue. We agreed to proceed with courage and good will. Iran has never left the negotiation table on its peaceful nuclear program.”

Mr. Araghchi made the comments following a meeting in Tehran with Rafael Grossi, the head of the U.N.’s atomic watchdog.

Analysts said that for all the history of bad blood with Mr. Trump, the Iranians appeared to want to keep the door to diplomacy open. Mr. Trump, too, appears interested, they said.

“Overall, everything is possible with Trump,” said Ali Vaez, the Iran director for the International Crisis Group. “He appears to be interested in a deal with Iran.” But some advisers, he said, may favor other approaches, among them increasing the pressure on Iran.

The two Iranian officials said that the meeting with Mr. Musk provided a workaround for Iran, allowing it to avoid sitting directly with an American official. Mr. Musk will, however, have an official role soon. He has been named as the co-director of a new government efficiency agency.

One Iranian Foreign Ministry official said that Ambassador Iravani told Mr. Musk during the meeting that he should obtain sanctions exemptions from the Treasury and bring some of his businesses to Tehran.

Iran’s mission to the United Nations said it would not publicly comment on the meeting.

NYT : Elon Musk Adds Microsoft to Suit Against OpenAI

Elon Musk Adds Microsoft to Suit Against OpenAI
In a new legal filing, the Tesla chief executive accuses the A.I. start-up of undermining antitrust law.

Elon Musk has amended a lawsuit he brought this year against OpenAI, escalating his yearslong feud with the maker of the online chatbot ChatGPT.

The amended complaint, filed on Thursday in federal court in Northern California, makes new antitrust claims against OpenAI and adds defendants, including the tech giant Microsoft and the venture capitalist Reid Hoffman.

Microsoft is a close partner of OpenAI, after investing more than $13 billion in the start-up. Mr. Hoffman is a Microsoft board member and previously served on the board of OpenAI.

The new legal filing also adds two plaintiffs to the suit alongside Mr. Musk: his start-up xAI, which competes with OpenAI, and Shivon Zilis, a former OpenAI board member. Ms. Zilis is now an executive at Mr. Musk’s brain implant company Neuralink and the mother of three of his children.

OpenAI and Mr. Hoffman did not immediately respond to requests for comment. Microsoft declined to comment.

Mr. Musk sued OpenAI in March in a state court in San Francisco, before withdrawing the suit without explanation. Seven weeks later, he filed a new suit in federal court, arguing that OpenAI violated federal racketeering laws by conspiring to defraud him.

Like the original suit, the federal complaint claimed that OpenAI and two of its founders, Sam Altman and Greg Brockman, breached the company’s founding contract by putting commercial interests ahead of the public good.

After joining with Mr. Musk to create OpenAI in 2015 and pledging to carefully develop artificial intelligence for the benefit of humanity, the suit claimed, Mr. Altman and Mr. Brockman abandoned this mission by entering its multibillion-dollar partnership with Microsoft.

Mr. Musk stepped away from OpenAI in 2018, before that partnership was created.

In the amended complaint, Mr. Musk argued that OpenAI is trying to eliminate competitors like xAI by insisting that its investors refrain from funding these rivals. He also argued that xAI had been harmed because OpenAI’s partnership with Microsoft allowed the two companies to trade “competitively sensitive information.”

Both Mr. Hoffman and Dee Templeton, a Microsoft vice president, had undermined antitrust laws because they were both involved with the boards of Microsoft and OpenAI, according to the complaint.

“The purpose of the prohibition on interlocking directorates is to prevent sharing of competitively sensitive information,” the complaint read.

In adding Ms. Zilis as a plaintiff in the suit, the new filing said that she repeatedly raised concerns over OpenAI’s dealings while serving as a board member. She left the OpenAI board last year.

>>> Europe : Brokers Upgrades & Downgrades - 15th of November 2024 V2(+)

>>> Up
* Aperam Raised to Outperform at Oddo BHF; PT 38 euros (+)
* Austevoll Seafood Raised to Buy at Kepler Cheuvreux (+)
* Aviva Raised to Buy at HSBC; PT 555 pence
* Burberry Raised to Neutral at Mediobanca SpA; PT 850 pence
* Burberry Raised to Neutral at UBS; PT 975 pence (+)
* CVC Capital Raised to Outperform at BNPP Exane (+)
* DSV Raised to Outperform at BNPP Exane; PT 1,700 kroner
* Elia Group Raised to Buy at KBC Securities; PT 124 euros (+)
* Ericsson Nikola Tesla Raised to Buy at Erste Group; PT 227 euros
* InterContinental Hotels Raised to Overweight at Barclays
* Microsoft Raised to Buy at First Shanghai; PT $500
* NKT Raised to Buy at Danske Bank Markets; PT 725 kroner (+)
* Orsted Raised to Hold at DNB Markets; PT 390 kroner
* Shell Raised to Outperform at Grupo Santander; PT 3,000 pence
* Spirax Raised to Buy at HSBC; PT 8,000 pence
* UBS Property Fund Direct Raised to Market Perform at ZKB (+)

>>> Down
* Applied Materials Cut to Neutral at Fubon; PT $200 (+)
* Carlsberg Cut to Underweight at Barclays; PT 698 kroner
* CVC Capital Cut to Neutral at Citi; PT 22.60 euros
* Givaudan Cut to Underweight at Barclays; PT 3,750 Swiss francs
* Hugo Boss Cut to Add at Baader Helvea; PT 45 euros
* MARR SpA Cut to Neutral at Mediobanca SpA; PT 12.50 euros
* Netflix Cut to Hold at First Shanghai; PT $823je sais pas
* Nice Ltd ADRs Cut to Neutral at Piper Sandler; PT $187
* Nice Ltd ADRs Cut to Market Perform at Oppenheimer
* SMA Solar Cut to Sell at DZ Bank; PT 10 euros
* Stadler Rail Cut to Hold at Bank Vontobel; PT 24 Swiss francs (+)
* Treatt Cut to Underweight at Barclays; PT 480 pence
* Unidata Cut to Accumulate at Banca Akros (+)
* Whitbread Cut to Equal-Weight at Barclays; PT 3,160 pence

>>> Initiation
* AbbVie Reinstated Outperform at Wolfe; PT $205
* Accelleron Rated New Outperform at Oddo BHF; PT 59 Swiss francs
* Allfunds Reinstated Buy at BofA; PT 8 euros (+)
* Also Rated New Buy at Kepler Cheuvreux; PT 330 Swiss francs (+)
* Amgen Reinstated Peerperform at Wolfe
* Bechtle Rated New Neutral at Redburn; PT 28.50 euros
* Biogen Reinstated Peerperform at Wolfe
* BioMarin Rated New Outperform at Wolfe; PT $95
* Bristol Myers Rated New Peerperform at Wolfe
* CDW Rated New Buy at Redburn; PT $230
* Eli Lilly Rated New Outperform at Wolfe; PT $1,000
* Gilead Rated New Outperform at Wolfe; PT $110
* Iberdrola Rated New Hold at Intesa Sanpaolo; PT 13.90 euros (+)
* Johnson & Johnson Rated New Outperform at Wolfe; PT $190
* Merck & Co Rated New Peerperform at Wolfe
* Pan African Rated New Overweight at ABSA Securities
* Per Aarsleff Rated New Buy at Nordea; PT 500 kroner
* Pfizer Rated New Underperform at Wolfe; PT $25
* Suedzucker Rated New Neutral at Matelan Research; PT 14.50 euros

>>> Call
* DSV Raised to Outperform at BNP on Schenker Synergies (+)
* JPMorgan Strategists See Soft Sales Beats in Reporting Season (+)

>>> Stoxx 600 Pre-Market Indications

  • Aegon (J060 TH) +3.1%
    • Aegon 3Q Adj. Oper Capital Generation EU336M Vs. EU354M Y/y
  • Rio Tinto (RIO1 TH) +1%
  • Porsche (P911 TH) -1%
    • NOTE: Porsche’s Taycan Stumble Demands a Bigger Fix: Chris Bryant
  • ASM Intl (AVS TH) -1%
  • Zalando (ZAL TH) -1.1%
  • Continental (CON TH) -1.2%
  • Hugo Boss (BOSS TH) -1.3%
  • Nemetschek (NEM TH) -1.3%
  • Infineon (IFX TH) -1.6%
  • ASML (ASME TH) -2%
  • Sanofi (SNW TH) -4%
    • Watch European Vaccine Stocks as Trump Picks Skeptic Kennedy
  • Bavarian Nordic (BV3 TH) -6.8%
    • Bavarian Nordic 3Q Revenue Misses Estimates
    • Watch European Vaccine Stocks as Trump Picks Skeptic Kennedy

>>> TradeGate Pre-Market Indications

DAX:
  • Siemens Energy (ENR TH) -1%
  • Infineon (IFX TH) -1.6%
MDAX:
  • Thyssenkrupp (TKA TH) -1%
  • TeamViewer (TMV TH) -1.2%
  • HelloFresh (HFG TH) -3.4%
SDAX:
  • Evotec SE (EVT TH) +21%
    • Evotec Receives $2.1 Billion Takeover Offer From Halozyme
  • Schaeffler (SHA0 TH) -1%
  • AUTO1 (AG1 TH) -1.2%
  • AlzChem Group AG (ACT TH) -2.1%
  • Dermapharm (DMP TH) -3.2%
  • PNE AG (PNE3 TH) -3.3%

>>> What to look at today - 15th of November 2024

Asian equities climbed, aided by some encouraging signs in China’s economy and a retreat in the dollar. The MSCI Asia Pacific Index rose 0.4%, its first gain this week, following data that showed China’s retail sales expanded at the strongest pace in eight months and property prices fell at a slower pace. Japanese benchmarks advanced about 0.8%, supported by weakness in the yen. US contracts slipped.
A gauge of the dollar halted a five-day gain that was helped by Federal Reserve Chair Jerome Powell’s comments that the central bank will be in no rush to cut interest rates. Friday’s action gives a welcome respite to emerging market assets after they were sold off for most of the week on US President-elect Donald Trump’s cabinet picks and uncertainties over China’s recovery.  US two-year yields were little changed after surging in the previous session as traders pared back their expectations for an interest-rate cut in December. More clarity on the Fed’s path can emerge as the US releases retail sales data and a host of Fed officials are set to speak.   A gauge of emerging markets equities was on pace for its worst week since June 2022, while a separate index of emerging markets currencies came close to erasing its gains for the year.  Among key earnings in Asia, Alibaba Group Holding Ltd. reports later Friday after another Chinese consumption bellwether JD.com Inc posted a moderate expansion in revenue.   China’s retail sales were “pretty good,” and a result of the central bank’s stimulus policy in late September, according to Jason Chan, senior investment strategist for Bank of East Asia. ““Fiscal stimulus is on the way, probably more details would be announced in December.” In commodities, oil headed for a weekly drop, weighed down by the impact of a stronger dollar and concerns the global market will flip to a glut next year. Gold held near a two-month low. Data earlier Thursday in the US showed producer prices exceeded consensus forecasts. Jobless claims were below expectations and touched the lowest level since May.   Several policymakers have urged a cautious approach to further rate cuts in comments this week, in light of a strong economy, lingering inflation concerns and broad uncertainty. Their comments come at a time when the equity market is showing signs of fatigue following a post-election surge that spurred calls for a pause, with several measures highlighting “stretched” trader optimism. In the US, the S&P 500 dropped 0.6%, while the Nasdaq 100 slipped 0.7%. Automakers like Tesla Inc. and Rivian Automotive Inc. slumped as Reuters reported Trump plans to eliminate the $7,500 consumer tax credit for electric-vehicle purchases. Walt Disney Co. jumped on a profit beat.  US After Hours AMAT -5.6% lower on earnings; ASTS -14.2%, GLOB -3.7% also lower; DPZ +7.3% as Berkshire Hathaway takes new position; DESP +16.3%, CWCO +5.1% higher on earnings.

Nikkei +0.28% Hang Seng +0.23% CSI -1.21% Shanghai -0.97% Shenzen -1.91%

Eur$ 1.0542 CNH 7.2441 CNY 7.2333 JPY 156.39 GBP 1.2674 CHF 0.8894 RUB 98.9494 TRY 34.3977 WTI$ 68.07 -0.92% Gold 2,566 +0.03% BTC 87,810 -0.45% ETH 3,058 -1.98%

S&P -0.50% Nasdaq -0.72% EuroStoxx -0.58% FTSE -0.42% Dax -0.46% SMI -0.64%

Macro :
- Oaktree’s Marks Sees Opportunity to Invest in China: Sohn Latest
- Oil supply to exceed demand by over 1m barrels a day in 2025
- Citigroup's Ties to Russian Oligarch Kerimov Draw Federal Scrutiny
- Large Swath of US Faces Power Supply Risk During Extreme Cold
- Fed Refuses to Back Basel Climate Plan, Leaving Talks in Limbo
- Vaccine Stocks Fall on Report RFK Jr. to be Named HHS Secretary
- Bitcoin Speculative Fervor Cools, Traders Await Next Trump Steps
- Michael Burry Boosts China Stakes But With Cautious Hedges

Keep an eye on :
- AGN NA : Aegon 3Q Adj. Oper Capital Generation EU336M Vs. EU354M Y/y
- AMUN FP : Amundi Buys Aixigo in Transaction Worth €149 Million
- ASTS US : AST SpaceMobile Buys Rocket Launches From Bezos’ Blue Origin
- BAVA DC : Bavarian Nordic 3Q Revenue Misses Estimates
- BESI NA : BE Semiconductor Declines to Comment on Merger Reports
- BA US : Boeing Hires Northrop Executive to Revamp Pentagon Projects -- WSJ
- BOL SS : Boliden Said to Close In on Deal to Buy Lundin’s European Mines
- BWO NO : BW Offshore Boosts FY Ebitda Forecast
- CGCBV FH : Cargotec to Sell €480 Million MacGregor Business to Triton
- CTEC LN : Convatec FY24, 25 View Unchanged Despite Local Medicare Coverage
- DSFIR NA : DSM-Firmenich Sold Stake in Robertet for Gross Amount of €115M
- DPZ US : Buffett’s Berkshire Buys Stakes in Domino’s Pizza, Pool Corp.
- EQNR NO : Equinor Says Halt to Review Rosebank Permit Risks Years of Delay
- EGLA IM : Eurogroup Laminations Sees FY Revenue Low End of EU900M
- EVT GY : Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction
- G IM : Generali 3Q Operating Profit Beats Estimates
- GVS IM : GVS 9M Ebitda EU76.6M Vs. EU67.3M Y/y
- HALO US : Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction
- JD US : JD.com Falls in HK as 4Q Investments Raise Concerns: Street Wrap
- KINVB SS : Kinnevik Chairman James Anderson Won’t Stand for Reelection
- LAND LN : Land Sec. 1H Revenue Profit Meets Estimates
- MRL SM : Merlin Properties 9M Net Income EU225.4M
- MSFT US : Elon Musk Adds Microsoft to Suit Against OpenAI
- BMPS IM : How Italy Swayed Its Tycoons to Pile Into Master Plan for Paschi
- NEOEN FP : Neoen Wins 164 MW of Solar Projects in Latest French Tender
- NEX FP : Nexans Holder Bpifrance Offers 1.09m Shares: Terms, placed @ 115/share
- NLFSK DC : Nilfisk 3Q Revenue Misses Estimates
- NOVOB DC : US Obesity Crisis Expected to Worsen by 2050, Study Warns
- PRY IM : Prysmian to Establish €3b EMTN Program to Refinance Debt
- RENE PL : REN 9M Net Income EU84.2M Vs. EU96.2M Y/y
- RBT FP : DSM-Firmenich Sold Stake in Robertet for Gross Amount of €115M
- SDZ SW : Sandoz Gets EU Approval for Biosimilar Afqlir
- SAN FP : Sanofi’s Sarclisa Gets EU Marketing Recommendation
- SAN FP : Sanofi’s Dupixent sBLA to Get FDA Review for CSU Treatment
- SCATC NO : Defic Globe, Scatec to Build 190MWP Solar Plants in Romania
- STLN SW : Swiss Steel Group Cuts 800 Jobs, Will Further Cut 530 Positions
- TOKMAN FH : Tokmanni 3Q Comparable Ebit Beats Estimates Tokmanni Will Pay Second Dividend of €0.38 Per Share
- VK FP : Vallourec 3Q Ebitda Misses Estimates
- VLA FP : Vaccine Stocks Fall on Report RFK Jr. to be Named HHS Secretary
- VKTX US : US Obesity Crisis Expected to Worsen by 2050, Study Warns
- WBD US : Webuild Maintains FY Ebitda Forecast
- WUW GY :

>>> Europe : Brokers Upgrades & Downgrades - 15th of November 2024

>>> Up
* Aviva Raised to Buy at HSBC; PT 555 pence
* Burberry Raised to Neutral at Mediobanca SpA; PT 850 pence
* DSV Raised to Outperform at BNPP Exane; PT 1,700 kroner
* Ericsson Nikola Tesla Raised to Buy at Erste Group; PT 227 euros
* InterContinental Hotels Raised to Overweight at Barclays
* Microsoft Raised to Buy at First Shanghai; PT $500
* Orsted Raised to Hold at DNB Markets; PT 390 kroner
* Shell Raised to Outperform at Grupo Santander; PT 3,000 pence
* Spirax Raised to Buy at HSBC; PT 8,000 pence

>>> Down
* Carlsberg Cut to Underweight at Barclays; PT 698 kroner
* CVC Capital Cut to Neutral at Citi; PT 22.60 euros
* Givaudan Cut to Underweight at Barclays; PT 3,750 Swiss francs
* Hugo Boss Cut to Add at Baader Helvea; PT 45 euros
* MARR SpA Cut to Neutral at Mediobanca SpA; PT 12.50 euros
* Netflix Cut to Hold at First Shanghai; PT $823je sais pas
* Nice Ltd ADRs Cut to Neutral at Piper Sandler; PT $187
* Nice Ltd ADRs Cut to Market Perform at Oppenheimer
* SMA Solar Cut to Sell at DZ Bank; PT 10 euros
* Treatt Cut to Underweight at Barclays; PT 480 pence
* Whitbread Cut to Equal-Weight at Barclays; PT 3,160 pence

>>> Initiation
* AbbVie Reinstated Outperform at Wolfe; PT $205
* Accelleron Rated New Outperform at Oddo BHF; PT 59 Swiss francs
* Amgen Reinstated Peerperform at Wolfe
* Bechtle Rated New Neutral at Redburn; PT 28.50 euros
* Biogen Reinstated Peerperform at Wolfe
* BioMarin Rated New Outperform at Wolfe; PT $95
* Bristol Myers Rated New Peerperform at Wolfe
* CDW Rated New Buy at Redburn; PT $230
* Eli Lilly Rated New Outperform at Wolfe; PT $1,000
* Gilead Rated New Outperform at Wolfe; PT $110
* Johnson & Johnson Rated New Outperform at Wolfe; PT $190
* Merck & Co Rated New Peerperform at Wolfe
* Pan African Rated New Overweight at ABSA Securities
* Per Aarsleff Rated New Buy at Nordea; PT 500 kroner
* Pfizer Rated New Underperform at Wolfe; PT $25
* Suedzucker Rated New Neutral at Matelan Research; PT 14.50 euros

>>> Call